I. Epidemiological profile

Population 2013 %
High transmission (>1 case per 1000 population) 197,000 0
Low transmission (1-1 cases per 1000 population) 5,790,000,000 42
Malaria-free (0 cases) 80,010,000 58
Total 1,385,937,000

II. Intervention policies and strategies

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Policies/strategies</th>
<th>Yes/No</th>
<th>Year adopted</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITN</td>
<td>ITN/LLINs distributed free of charge</td>
<td>Yes</td>
<td>2003</td>
</tr>
<tr>
<td></td>
<td>ITN/LLINs distributed to all age groups</td>
<td>Yes</td>
<td>2008</td>
</tr>
<tr>
<td>IRS</td>
<td>IRS is recommended</td>
<td>Yes</td>
<td>2008</td>
</tr>
<tr>
<td></td>
<td>LDT is authorized for IRS</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>Larval control</td>
<td>Use of larval control recommended</td>
<td>No</td>
<td>–</td>
</tr>
<tr>
<td>IPT</td>
<td>IPT used to prevent malaria during pregnancy</td>
<td>N/A</td>
<td>–</td>
</tr>
</tbody>
</table>

Diagnosis

At high risk: patients of all ages should receive diagnostic test
Malaria diagnosis: free of charge in the public sector

Treatment

ACT is free for all age groups

Antimalarial-based monotherapies withdrawn

Single dose of primaquine is used as gametocidal medicine for P. falciparum

Primaquine is used for radical treatment of P. vivax

G6PD test is a requirement before treatment with primaquine

Directly observed treatment with primaquine is undertaken

System for monitoring of adverse reactions to antimalarials exists

Parasites and vectors

Major Plasmodium species: P. falciparum (73%), P. vivax (23%)

Programme phase

Control

Reported confirmed cases: 40,866
Reported deaths: 23

III. Financing

Source of financing

<table>
<thead>
<tr>
<th>Year</th>
<th>Government</th>
<th>Global Fund</th>
<th>World Bank</th>
<th>USAID/PMI</th>
<th>WHO/UNICEF</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>15%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
<tr>
<td>2007</td>
<td>16%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
<tr>
<td>2008</td>
<td>17%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
<tr>
<td>2009</td>
<td>18%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
<tr>
<td>2010</td>
<td>19%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
<tr>
<td>2011</td>
<td>20%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
<tr>
<td>2012</td>
<td>21%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
<tr>
<td>2013</td>
<td>22%</td>
<td>20%</td>
<td>35%</td>
<td>10%</td>
<td>15%</td>
<td>5%</td>
</tr>
</tbody>
</table>

IV. Coverage

ITN and IRS coverage

Proportion (%)

- At high risk protected with ITNs
- Households with at least one ITN
- All age groups who slept under an ITN (survey)
- At high risk protected with IRS

Cases tracked

- % of fever cases <5 sentinel treatment at public HF (survey)
- Reporting completeness

Test positivity

- Parasite prevalence (survey)
- Slide positivity rate
- RDT positivity rate

V. Impact

Confirmed malaria cases per 1000 and ABER

- ABER (microscopy & RDT)
- Cases (all species)
- Cases (P. vivax)

Malaria admissions and deaths

- Admissions (all species)
- Admissions (P. vivax)
- Deaths (all species)
- Deaths (P. vivax)

Impact: Achieved >75% decrease in case incidence in 2013